LIALDA/MEZAVANT XL
We focus on meeting unmet needs, and developing effective treatments for specialist physicians, and rare diseases.
LIALDA/MEZAVANT XL
US ASA market share is now 14.1% as at December 2008*
“Having medication that I take just once a day has helped me regain control and enjoy quality time with my young daughter.”
Sara Logan
LIALDA/MEZAVANT XL is the first and only oral once a day treatment for the induction of remission in patients with active mild to moderate ulcerative colitis. For more information on Shire products visit http://www.shire.com/shire/products/
*Source IMS NPA
